Literature DB >> 8380394

Cryoglobulinemia with vasculitis associated with hepatitis C virus infection.

P Marcellin1, V Descamps, M Martinot-Peignoux, D Larzul, L Xu, N Boyer, B N Pham, B Crickx, L Guillevin, S Belaich.   

Abstract

Essential mixed cryoglobulinemia is frequently associated with chronic hepatitis. This report presents four cases of cryoglobulinemia with vasculitis associated with chronic hepatitis related to hepatitis C virus infection. Hepatitis C virus infection was ascertained in the four patients by both the presence in the serum of anti-HCV antibodies detected by the four-antigen recombinant immunoblot assay and of HCV RNA detected by polymerase chain reaction. In two patients tested, anti-HCV antibodies were not detected after centrifugation in the purified cryoglobulin but were detected in the supernatant. HCV RNA was detected in the purified cryoglobulin in all four patients and was detected in the supernatant in three patients. In one patient receiving recombinant interferon alfa, serum aminotransferases normalized and cryoglobulin disappeared; in another patient receiving recombinant interferon alfa, serum aminotransferases remained high and the cryoglobulin persisted. The presence of HCV RNA in the cryoglobulin and the parallelism of the changes of the cryoglobulinemia and of the serum aminotransferases during recombinant interferon alfa administration suggest that HCV infection is responsible for the production of cryoglobulinemia and vasculitis. It is proposed that HCV infection is a cause of cryoglobulinemia associated with chronic hepatitis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8380394     DOI: 10.1016/0016-5085(93)90862-7

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  20 in total

1.  Clinical guidelines on the management of hepatitis C.

Authors:  J C Booth; J O'Grady; J Neuberger
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

Review 2.  Nonhepatic manifestations and combined diseases in HCV infection.

Authors:  S J Hadziyannis
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

3.  Interferon-alpha therapy for chronic hepatitis C in special patient populations.

Authors:  P Marcellin; N Boyer; J P Behamou; S Erlinger
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

Review 4.  Mode of hepatitis C virus infection, epidemiology, and chronicity rate in the general population and risk groups.

Authors:  H L Tillmann; M P Manns
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

Review 5.  Vth International Symposium on Sjögren's syndrome. Clinical aspects and therapy.

Authors:  R I Fox
Journal:  Clin Rheumatol       Date:  1995-07       Impact factor: 2.980

6.  Antiviral treatment down-regulates peripheral B-cell CD81 expression and CD5 expansion in chronic hepatitis C virus infection.

Authors:  Eli Zuckerman; Aharon Kessel; Gleb Slobodin; Edmond Sabo; Daniel Yeshurun; Elias Toubi
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Active hepatitis C virus infection in bone marrow and peripheral blood mononuclear cells from patients with mixed cryoglobulinaemia.

Authors:  A Gabrielli; A Manzin; M Candela; M L Caniglia; S Paolucci; M G Danieli; M Clementi
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

8.  Long-term results of therapy with interferon alpha for cryoglobulinemia associated with hepatitis C virus infection.

Authors:  J M Durand; E Cretel; G Kaplanski; P Lefevre; F Retornaz; J Soubeyrand
Journal:  Clin Rheumatol       Date:  1994-03       Impact factor: 2.980

9.  The association of complement activation at a low temperature with hepatitis C virus infection in comparison with cryoglobulin.

Authors:  K Ueda; H Nakajima; T Nakagawa; A Shimizu
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

Review 10.  The hepatitis C virus infection as a systemic disease.

Authors:  Anna Linda Zignego; Laura Gragnani; Carlo Giannini; Giacomo Laffi
Journal:  Intern Emerg Med       Date:  2012-10       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.